This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. With 18 of the industry’s top 25 companies achieving year-over-year revenue gains, Q1 came close to matching the final quarter of last year, when 21 of the top 25 companies showed increases.
While adopting new technology is obviously a big part of healthcare innovation teams’ work, there are plenty of worthwhile initiatives that don’t involve advanced technologies, pointed out Dan Shoenthal, chief innovation officer at MD Anderson Cancer Center. The post Innovation Doesn’t Always Have To Involve The Latest Tech, MD Anderson Exec Says appeared first on MedCity News.
China-made PD-1 inhibitors just can’t get a clean pass through the FDA. | China-made PD-1 inhibitors continue to struggle at the FDA. This week, the U.S. agency rejected Elevar Therapeutics and Jiangsu Hengrui Pharma's PD-1 combination in liver cancer.
The dangers of polypharmacy and its increasingly wide reach across the American population make it imperative that we enhance the accuracy and efficiency of medication reconciliation processes. The post It’s Past Time to Prevent Polypharmacy in U.S. Healthcare appeared first on MedCity News.
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
A fire broke out Thursday on the roof of a building under construction at Novo Nordisk’s key manufacturing hub in Kalundborg, Denmark, where the drugmaker is currently charting a multi-year expansi | A fire broke out Thursday on the roof of a building under construction at Novo Nordisk’s key manufacturing hub in Kalundborg, Denmark, where the drugmaker is currently charting a multi-year expansion to boost capacity for its blockbuster diabetes and obesity drugs.
Right on the heels of a similar move by Johnson & Johnson, GSK is offloading the rest of its stake in the consumer healthcare business it spun out back in 2022. | GSK plans to sell its remaining holding in consumer healthcare spinoff Haleon, the British drugmaker said Thursday. After prior divestments, GSK currently owns about 385 million Haleon shares.
After admitting to the crime four years ago, a former Sandoz executive will avoid hard time for his part in a generic drug price-fixing scheme. | Hector Kellum agreed to cooperate with federal investigators in 2020, admitting his part in a massive generics price-fixing scheme that spanned many companies.
Johnson & Johnson’s Proteologix acquisition adds a pipeline of bispecific antibodies, including an experimental treatment for asthma and atopic dermatitis. It’s the latest M&A deal involving molecules addressing TSLP, a key signaling protein involved in inflammation. The post J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition appeared first on MedCity News.
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer. | The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer, where the CD19 CAR-T will again compete with Gilead Sciences and Novartis drugs.
Virginia Medicaid beneficiaries now have access to Aeroflow Health’s breast pumps and lactation consultants. The post Virginia Medicaid Taps Aeroflow Health for Lactation Services appeared first on MedCity News.
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
At the MedCity INVEST conference from May 21-22 at the Ritz Carlton in Chicago, a panel discussion sponsored by Quantum Health will share how employers are addressing value-based care. The post Employers Will Share Value-Based Care Strategies at MedCity INVEST appeared first on MedCity News.
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
May 16, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, was named a Bronze Stevie® Award winner for Customer Service Department of the Year in the 22nd annual American Business Awards ®. The American Business Awards are the premier business awards program in the U.S. Nicknamed the “Stevies” for the Greek word meaning “crowned,” the competition receives over 12,000 entries each year from organizations in 70 countries.
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Hepatitis Awareness Month is designed to raise awareness of viral hepatitis and promote testing and vaccination while decreasing the stigma against the virus.
As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.
Chief Strategy Officers (CSOs) for health systems face the constant challenge of finding new revenue streams to cover the increasing costs of high- quality healthcare. To help tackle the problem, they are turning to predictive analytics for deep insights that can drive strategic decisions and open new revenue channels. By leveraging predictive analytics, CSOs can identify under-served areas, develop new service lines, enhance telemedicine offerings, and foster partnerships and collaborative ve
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
I still remember the day vividly – it was a rainy Tuesday afternoon, and I was scheduled for a pharmaceutical sales call that I had been dreading for weeks. My client was known for being tough, and I had rehearsed my pitch countless times. Little did I know, this particular call would turn out to be a turning point in my career, teaching me invaluable lessons about the art of conversation and the true essence of building relationships in the pharmaceutical industry.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content